Payment overview · 2025
General Payments
$151.36
9 reported records · 5 companies
Healthcare provider profile · identity verified
Ryan Ray Turner, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLANCHARD, OK · NPI 1780613109
Verified facts
What the public records show
CMS Open Payments records show Ryan Ray Turner, MD received $151.36 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.07 | 33.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.00 | 23.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.65 | 22.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.74 | 11.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.90 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.36 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 557 | 153 |
| Lisinopril | Lisinopril | 366 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 96 |
| Omeprazole | Omeprazole | 340 | 96 |
| Gabapentin | Gabapentin | 337 | 82 |
| Methylprednisolone | Methylprednisolone | 263 | 188 |
| Metformin Hcl | Metformin Hcl | 250 | 74 |
| Losartan Potassium | Losartan Potassium | 242 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 68 |
| Furosemide | Furosemide | 213 | 67 |
| Potassium Chloride | Potassium Chloride | 190 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 51 |
| Montelukast Sodium | Montelukast Sodium | 169 | 52 |
| Meloxicam | Meloxicam | 166 | 50 |
| Eliquis | Apixaban | 159 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 51 |
| Lovastatin | Lovastatin | 145 | 40 |
| Trazodone Hcl | Trazodone Hcl | 143 | 35 |
| Alprazolam | Alprazolam | 141 | 18 |
| Simvastatin | Simvastatin | 141 | 39 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 139 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 27 |
| Glipizide | Glipizide | 123 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 25 |
| Ezetimibe | Ezetimibe | 106 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 26 |
| Clonazepam | Clonazepam | 97 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 22 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Carvedilol | Carvedilol | 88 | 26 |
| Allopurinol | Allopurinol | 85 | 21 |
| Famotidine | Famotidine | 82 | 21 |
| Glipizide Er | Glipizide | 81 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 18 |
| Celecoxib | Celecoxib | 66 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 19 |
| Sertraline Hcl | Sertraline Hcl | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 61 | suppressed |
| Atenolol | Atenolol | 60 | 18 |
| Tramadol Hcl | Tramadol Hcl | 58 | 25 |
| Clonidine Hcl | Clonidine Hcl | 57 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 12 |
| Chlorthalidone | Chlorthalidone | 55 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 25 |
| Temazepam | Temazepam | 53 | suppressed |
| Jardiance | Empagliflozin | 51 | 13 |
| Ozempic | Semaglutide | 50 | suppressed |
| Fenofibrate | Fenofibrate | 49 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 11 |
| Bupropion Xl | Bupropion Hcl | 47 | 11 |
| Donepezil Hcl | Donepezil Hcl | 47 | 13 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 13 |
| Estradiol | Estradiol | 45 | 13 |
| Cephalexin | Cephalexin | 44 | 30 |
| Prednisone | Prednisone | 44 | 34 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 35 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 17 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 15 |
| Farxiga | Dapagliflozin Propanediol | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 20 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 12 |
| Meclizine Hcl | Meclizine Hcl | 26 | 19 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Metronidazole | Metronidazole | 25 | 18 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Nabumetone | Nabumetone | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.36 · 9 records | PFIZER INC. | ABRYSVO, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, PREVNAR 20, The Cologuard Plus Collection Kit, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error